1. *Deadline:* Applications shall be considered as meeting the deadline if they are either:

(a) Received on or before the deadline date; or

(b) Sent on or before the deadline date and received in time for submission to the objective review group. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

2. Late Application: Applications that do not meet the criteria in 1.(a) or 1.(b) above are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicant.

Where To Obtain Additional Information

To receive additional written information, call (404) 332–4561. You will be asked to leave your name, address, and telephone number. Please refer to *Announcement 741.* You will receive a complete program description, information on application procedures, and application forms. If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from Albertha Carey, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, Mail Stop E–18, Atlanta, Georgia 30305, telephone (404) 842–6591; electronic mail at ayc1@cdc.gov.

Technical assistance may be obtained from Colette Zyrkowski, Division of Public Health Surveillance and Informatics, Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), Mail Stop C–08, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone (404) 639–0080; fax (404) 639–1546; or Internet or CDC WONDER electronic mail at coz1@cdc.gov.

You may obtain this announcement from one of two Internet sites on the actual publication date: CDC's homepage at http://www.cdc.gov or the Government Printing Office homepage (including free on-line access to the **Federal Register** at http://www.access.gpo.gov).

Please refer to *Program Announcement 741* when requesting information and submitting an application.

Potential applicants may obtain a copy of Healthy People 2000 (Full Report; Stock No. 017–001–00474–0) or Healthy People 2000 (Summary Report; Stock No. 017–001–00473–1) referenced in the ''Introduction'' through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 512–1800. Centers for Disease Control and Prevention Guidelines for Evaluating Surveillance Systems can be found in the Morbidity and Mortality Weekly Report 1988; 37 (suppl. no. S–5).

Dated: June 16, 1997.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–16169 Filed 6–19–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Subcommittee on Intimate Partner Violence Prevention Research and the Injury Research Grant Review Committee (IRGRC): Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee and conference call committee meetings.

Name: Subcommittee on Intimate Partner Violence Prevention Research of the IRGRC.

Times and Dates: 6:30 p.m.–9 p.m., July 13, 1997. 8 a.m.–4 p.m., July 14, 1997.

Place: Renaissance Atlanta Hotel-Concourse, One Hartsfield Centre Parkway, Atlanta, Georgia 30354.

Status: Open: 6:30 p.m.–6:45 p.m., July 13, 1997.

Closed: 6:45 p.m.–9 p.m., July 13, 1997, through 4 p.m., July 14, 1997.

Purpose: The Subcommittee advises IRGRC on the technical and scientific merit of injury prevention research grant applications on intimate partner violence prevention.

Matters to be Discussed: Agenda items include a description of the Subcommittee's responsibilities and review process, and review of grant applications.

Name: Injury Research Grant Review Committee.

Time and Date: 2 p.m.–4 p.m., July 16, 1997.

Place: National Center for Injury Prevention and Control (NCIPC), CDC, Koger Center, Vanderbilt Building, 1st Floor, Conference Room 1006, 2939 Flowers Road, South, Atlanta, Georgia 30341. (Exit Chamblee-Tucker Road off I–85.)

Status: Open: 2 p.m.–2:15 p.m., July 16, 1997.

Closed: 2:15 p.m.–4 p.m., July 16, 1997.

Purpose: This committee is charged with advising the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the scientific merit and technical feasibility of grant applications received from academic institutions and other public and private profit and nonprofit organizations, including State and local government agencies, to conduct specific injury research that focus on prevention and control and to support injury prevention research centers.

Matters to be Discussed: Agenda items include a budget update, recent awards, report of the Subcommittee on Intimate Partner and Violence Prevention Research, description of the review process, future meeting dates, and review of grant applications.

Beginning at 2:15 p.m., July 13, through 4 p.m., July 14, the Subcommittee on Intimate Partner Violence Prevention Research of the IRGRC will meet and from 2:15–4 p.m., July 16, IRGRC will meet to conduct a review of grant applications. These portions of the meetings will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Richard W. Sattin, M.D., Executive Secretary, IRGRC, NCIPC, CDC, 4770 Buford Highway, NE, M/S K58, Atlanta, Georgia 30341–3724, telephone 770/488–4580.

Dated: June 13, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–16171 Filed 6–19–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 92N–0251]

Agency Information Collection Activities; Submission for OMB Review; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the collection of information by July 21, 1997.

ADDRESSES: Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attention: Desk Officer for FDA.

FOR FURTHER INFORMATION CONTACT: Mark L. Pincus, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1471.

SUPPLEMENTARY INFORMATION: In compliance with section 3507 of the PRA (44 U.S.C. 3507), FDA has submitted the following proposed collection of information to OMB for review and clearance:

Title: Electronic Records; Electronic Signatures—21 CFR Part 11

Description: FDA regulations in part 11 (21 CFR part 11) provide criteria for acceptance of electronic records, electronic signatures, and handwritten signatures executed to electronic records in place of paper records. The regulations will become effective on August 20, 1997. Under these regulations, records and reports may be submitted to FDA electronically, provided the agency has stated its ability to accept the records electronically in an agency-established public docket and that the other requirements of part 11 are met.

The recordkeeping provisions in part 11 (§§ 11.10, 11.30, 11.50, and 11.300) require standard operating procedures to assure appropriate use of, and precautions for, systems using electronic records and signatures. The reporting provision (§ 11.100) requires persons to certify in writing to FDA that they will regard electronic signatures used in their systems as the legally binding equivalent of traditional handwritten signatures.

Description of Respondents: Businesses and other for-profit organizations, State or local governments, Federal agencies, and nonprofit institutions.

Most of the burden created by the information collection provisions of this final rule will be a one-time burden associated with the creation of standard operating procedures, validation, and certification. The agency anticipates that the use of electronic media will result in a substantial net reduction in the paperwork burden associated with maintaining FDA-required records.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN

21 CFR Section	Frequency per Recordkeeper	Hours per Recordkeeper	Total Hours
11.10	50	40	2,000
11.30	50	40	2,000
11.50	50	40	2,000
11.300	50	40	2,000
Total Recordkeeping Burden Hours			8,000

There are no capital costs or operating and maintenance costs associated with this collection of information.

TABLE 2.—ESTIMATED ANNUAL REPORTING BURDEN

21 CFR Section	No. of Respondents	Annual Frequency per Response	Hours per Response
11.100	1,000	1	1,000
Total Reporting Burden Hours			1,000

There are no capital costs or operating and maintenance costs associated with this information collection.

Dated: June 16, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–16178 Filed 6–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0170]

Toyo-Morton, Ltd.; Filing of Food Additive Petition; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of April 30, 1997 (62 FR 23467). The document announced that Toyo-Morton, Ltd., filed a petition proposing that the food additive regulations be amended to provide for the safe use of polyester-epoxy-urethane adhesive for use as a nonfood contact layer of laminated articles intended for use in contact with food. The document published with an incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: LaJuana D. Caldwell, Office of Policy (HF–27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2994.

In FR Doc. 97–11078, appearing on page 23467 in the **Federal Register** of Wednesday, April 30, 1997, the following correction is made:

1. On page 23467, in the third column, Docket No. ''97C–0171'' is corrected to read ''97F–0170''.

Dated: June 9, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 97–16236 Filed 6–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.